Granisetron (tablet): Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{DrugProjectFormSinglePage01
{{DrugProjectFormSinglePage01
|authorTag={{SC}}
|authorTag={{SC}}
|genericName=Granisetron
|aOrAn=an
|drugClass=antiemetic
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Granisetron (tablet) in adult patients.
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of Granisetron (tablet) in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Granisetron (tablet) in adult patients.
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of Granisetron (tablet) in adult patients.

Revision as of 19:37, 14 May 2015

Granisetron (tablet)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

For patient information regarding Granisetron, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shanshan Cen, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Granisetron (tablet) is an antiemetic that is FDA approved for the {{{indicationType}}} of {{{indication}}}. Common adverse reactions include {{{adverseReactions}}}.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

{{{fdaLIADAdult}}}

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Granisetron (tablet) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Granisetron (tablet) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

{{{fdaLIADPed}}}

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Granisetron (tablet) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Granisetron (tablet) in pediatric patients.

Contraindications

{{{contraindications}}}

Warnings

{{{warnings}}}

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trials Experience of Granisetron (tablet) in the drug label.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Granisetron (tablet) in the drug label.

Drug Interactions

{{{drugInteractions}}}

Use in Specific Populations

Pregnancy

{{{useInPregnancyFDA}}}

Labor and Delivery

There is no FDA guidance on the use of Granisetron (tablet) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Granisetron (tablet) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Granisetron (tablet) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Granisetron (tablet) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Granisetron (tablet) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Granisetron (tablet) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Granisetron (tablet) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Granisetron (tablet) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Granisetron (tablet) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance on the use of Granisetron (tablet) in patients who are immunocompromised.

Administration and Monitoring

Administration

{{{administration}}}

Monitoring

There is limited information regarding Monitoring of Granisetron (tablet) in the drug label.

Overdosage

{{{overdose}}}

Pharmacology

{{{drugBox}}}

Mechanism of Action

{{{mechAction}}}

Structure

{{{structure}}}

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Granisetron (tablet) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Granisetron (tablet) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Granisetron (tablet) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Granisetron (tablet) in the drug label.

How Supplied

{{{howSupplied}}}

Images

Package and Label Display Panel

{{{packLabel}}}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Granisetron (tablet) in the drug label.

Precautions with Alcohol

Alcohol-Granisetron (tablet) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

®

Look-Alike Drug Names

A® — B®

Drug Shortage Status

References

The contents of this FDA label are provided by the National Library of Medicine.